Novo Nordisk strategically resolved its patent lawsuit against Hims & Hers not just to stop the sale of compounded semaglutide, but to transform Hims into a direct-to-consumer channel for its brand-name drug, Wegovy. This move turns a legal and market threat into a lucrative partnership, expanding their reach directly to cash-pay customers.
Despite Boris Nikolic's deep ties to Jeffrey Epstein, his strong financial track record and connections enabled him to raise a $100M fund. This highlights a systemic bias where male VCs with a history of generating returns can overcome severe reputational damage, a privilege often unavailable to female fund managers.
The departure of controversial FDA official Vinay Prasad did not resolve the agency's underlying policy conflicts. There was a significant 'dissonance' between leadership's public calls for regulatory flexibility for rare diseases and the stricter actions being taken. This suggests the challenge is systemic, not merely personnel-driven, a sentiment echoed by Senator Ron Johnson's ongoing investigation.
A lead investor's influence can place startup founders in a difficult position, compelling them to accept investments from controversial sources they might otherwise reject. The example of Curie Bio introducing a portfolio company to Boris Nikolic's fund highlights the power imbalance, where founders may lack the leverage to refuse capital for fear of jeopardizing their primary funding relationship.
Prominent VC Alexis Borisi backed Boris Nikolic's new fund based on personal loyalty and trust, despite public red flags about Nikolic's ties to Jeffrey Epstein. Borisi's vouching acted as a 'cosigner', enabling Nikolic to raise $100M. This demonstrates how personal relationships in venture capital can supersede standard reputational due diligence, creating significant downstream risk for LPs and portfolio companies.